Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction

– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors –– Proceeds will support ongoing comprehensive mid to late-stage clinical development program for ESK-001 in plaque psoriasis, systemic lupus erythematosus (SLE) and uveitis –– Alumis will continue to explore ESK-001’s potential application in other immune-mediated diseases, […]

Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years

Ken Song almost never got into radiopharmaceuticals. But after back-to-back phone calls from venture capital leaders at Versant and venBio in March 2020, the repeat life sciences CEO took a deep dive into the field, which at that point was outside the radar of most people in drug development. Those calls worked, and Song would […]

Attralus Closes $56 Million Financing

SAN FRANCISCO – February 06, 2024 – Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $56 million financing. The financing round was led by new investor Alpha Wave Ventures and also included Bristol Myers Squibb (BMY). Existing investors also […]

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis […]

35Pharma Announces Clearance of Clinical Trial Application for HS135, Best-in-Class Activin and GDF Inhibitor

Montréal, QC, Canada (Jan 03, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate HS135-001, a Phase 1 study of HS135 in healthy volunteers.  “Overactive Activin and GDF signalling is a genetically and clinically validated […]

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

PRINCETON, N.J. & SAN DIEGO–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was […]

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s […]

RayzeBio Announces Closing of Upsized $358 Million IPO

SAN DIEGO–(BUSINESS WIRE)–Sep. 19, 2023– RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from […]

Introducing Fierce Biotech’s 2023 Fierce 15 – FOG and RayzeBio

It’s been a tough year for biotech, so how about a little good news? In between all the layoffs, restructurings and last-ditch strategic option hunting, we wanted to take a moment to shine a spotlight on 15 innovative and truly fierce biotechs. Everyone we talk to in the Fierce Biotech universe tells us that science […]

Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis

SAN DIEGO, August 16, 2023 — Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for AlloNK® (also known as AB-101), in combination with rituximab […]